Coronavirus Disease 2019 Convalescent Plasma Utilization in the United States: Data From the National Inpatient Sample.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Volume: 77

Issue: 2

Year of Publication: 2023

Affiliated Institutions:  Division of Transfusion Medicine, Department of Pathology, Johns Hopkins University, Baltimore, Maryland, USA. Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Abstract summary 

Coronavirus disease 2019 (COVID-19) convalescent plasma (CCP) use between October and December 2020 was characterized using the National Inpatient Sample database. CCP was administered in 18.0% of COVID-19-associated hospitalizations and was strongly associated with older age and increased disease severity. There were disparities in the receipt of CCP by race and ethnicity, geography, and insurance.

Authors & Co-authors:  Bloch Evan M EM Goel Ruchika R Zhu Xianming X Patel Eshan U EU Shoham Shmuel S Sullivan David J DJ Gebo Kelly A KA Casadevall Arturo A Tobian Aaron A R AAR

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Senefeld JW, Johnson PW, Kunze KL, et al. . Access to and safety of COVID-19 convalescent plasma in the United States expanded access program: a national registry study. PLoS Med 2021; 18:e1003872.
Authors :  9
Identifiers
Doi : 10.1093/cid/ciad185
SSN : 1537-6591
Study Population
Male,Female
Mesh Terms
Humans
Other Terms
COVID-19;COVID-19 serotherapy;SARS-CoV-2;blood donors;blood transfusion
Study Design
Cross Sectional Study
Study Approach
Country of Study
Publication Country
United States